...
首页> 外文期刊>Journal of microbiology, immunology, and infection: Wei mian yu gan ran za zhi >Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial
【24h】

Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial

机译:口服Nemonxacin的安全性和疗效与左氧氟沙星治疗社区获得的肺炎:第3阶段,多中心,随机,双盲,双伪,主动控制,非劣势试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Purpose: Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. The purpose of this study was to assess the efficacy and safety of nemonoxacin compared with levofloxacin in patients with CAP.
机译:背景/目的:Nemonoxacin是一种新的非氟化喹诺酮,具有优异的体外活性,针对社区获得的肺炎(帽),尤其是革兰氏阳性分离株。 本研究的目的是评估Nemonoxacin与帽中左氧氟沙星相比的疗效和安全性。

著录项

  • 来源
  • 作者单位

    Fudan Univ Huashan Hosp Inst Antibiot 12 Middle Wulumuqi Rd Shanghai 200040 Peoples R China;

    Guilin Med Univ Dept Resp Med Affiliated Hosp Guangxi Peoples R China;

    Gen Hosp Shenyang Mil Area Command Dept Resp Med Shenyang Liaoning Peoples R China;

    Peking Univ Inst Clin Pharmacol Hosp 1 Beijing Peoples R China;

    Far Eastern Mem Hosp Dept Internal Med New Taipei Taiwan;

    Cent Hosp Jinan Dept Resp Med Jinan Shandong Peoples R China;

    Capital Med Univ Beijing Chao Yang Hosp Dept Resp Med Beijing Peoples R China;

    Cheng Ching Gen Hosp Dept Chest Med Taichung Taiwan;

    Cent S Univ Xiangya Hosp 3 Dept Resp Med Changsha Hunan Peoples R China;

    Peking Univ Dept Resp Med Peoples Hosp Beijing Peoples R China;

    Fudan Univ Huashan Hosp Inst Antibiot 12 Middle Wulumuqi Rd Shanghai 200040 Peoples R China;

    Fudan Univ Huashan Hosp Inst Antibiot 12 Middle Wulumuqi Rd Shanghai 200040 Peoples R China;

    TaiGen Biotechnol Co Ltd Taipei Taiwan;

    Fudan Univ Huashan Hosp Inst Antibiot 12 Middle Wulumuqi Rd Shanghai 200040 Peoples R China;

    China Med Univ Shengjing Hosp Dept Resp Med Shenyang Liaoning Peoples R China;

    Shanghai Univ Tradit Chinese Med Putuo Hosp Dept Resp Med Shanghai Peoples R China;

    Zhejiang Univ Affiliated Hosp 1 Dept Resp Med Zhejiang Peoples R China;

    Guangzhou Red Cross Hosp Dept Resp Med Guangzhou Guangdong Peoples R China;

    Fudan Univ Dept Resp Med Huadong Hosp Shanghai Peoples R China;

    Cent Hosp Changsha Dept Resp Med Changsha Hunan Peoples R China;

    Tongji Univ East Hosp Dept Resp Med Shanghai Peoples R China;

    Gansu Prov Peoples Hosp Dept Resp Med Lanzhou Gansu Peoples R China;

    Jiangxi Prov Peoples Hosp Dept Resp Med Nanchang Jiangxi Peoples R China;

    Sichuan Univ West China Hosp Ctr Infect Dis Chengdu Sichuan Peoples R China;

    Shanxi Med Univ Affiliated Hosp 1 Dept Resp Med Taiyuan Shanxi Peoples R China;

    Wenzhou Med Univ Affiliated Hosp 2 Dept Resp Med Wenzhou Zhejiang Peoples R China;

    Hainan Prov Peoples Hosp Dept Resp Med Haikou Hainan Peoples R China;

    Wuhan Gen Hosp Guangzhou Command Dept Resp Med Wuhan Hubei Peoples R China;

    Peoples Hosp Shenzhen Dept Resp Med Shenzhen Guangdong Peoples R China;

    Hainan Med Univ Affiliated Hosp Dept Resp Med Haikou Hainan Peoples R China;

    Second Artillery Gen Hosp Dept Resp Med Beijing Peoples R China;

    Hunan Prov Peoples Hosp Dept Resp Med Changsha Hunan Peoples R China;

    Capital Med Univ Dept Resp Med Beijing Anzhen Hosp Beijing Peoples R China;

    Nanjing Gen Hosp Dept Resp Med Nanjing Jiangsu Peoples R China;

    Hubei Univ Med Taihe Hosp Dept Resp Med Shiyan Hubei Peoples R China;

    Nanchang Univ Dept Resp Med Affiliated Hosp 2 Nanchang Jiangxi Peoples R China;

    Changzheng Hosp Dept Resp Med Shanghai Peoples R China;

    Third Mil Med Univ Daping Hosp Dept Resp Med Chongqing Peoples R China;

    Zhongshan Univ Affiliated Hosp 2 Dept Resp Med Zhongshan Guangdong Peoples R China;

    Fujian Med Univ Affiliated Hosp 1 Dept Resp Med Fuzhou Fujian Peoples R China;

    Chongqing Med Univ Dept Infect Dis Affiliated Hosp 1 Chongqing Peoples R China;

    Lanzhou Univ Affiliated Hosp 2 Dept Resp Med Lanzhou Gansu Peoples R China;

    Xinjiang Med Univ Affiliated Hosp 1 Dept Resp Med Xinjiang Peoples R China;

    Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6 Dept Resp Med Shanghai Peoples R China;

    Peking Union Med Coll Hosp Dept Resp Med Beijing Peoples R China;

    Wuhan Univ Peoples Hosp Dept Resp Med Wuhan Hubei Peoples R China;

    Chi Mei Med Ctr Dept Med Res Tainan Taiwan;

    Triserv Gen Hosp Dept Internal Med Div Pulm Med Taipei Taiwan;

    Chung Shan Med Univ Hosp Dept Internal Med Div Chest Taichung Taiwan;

    Taichung Vet Gen Hosp Dept Internal Med Taichung Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med Dept Internal Med Kaohsiung Taiwan;

    China Med Univ Hosp Dept Internal Med Div Infect Dis Taipei Taiwan;

    Cheng Hsin Gen Hosp Taipei Taiwan;

    E Da Hosp Sect Infect Dis Dept Med Kaohsiung Taiwan;

    Natl Taiwan Univ Hosp Dept Internal Med Taipei Taiwan;

    Ditmanson Med Fdn Dept Internal Med Chia Yi Christian Hosp Chiayi Taiwan;

    Taipei Vet Gen Hosp Dept Chest Med Taipei Taiwan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 基础医学;
  • 关键词

    Clinical outcome; Community-acquired pneumonia; Levofloxacin; Nemonoxacin; Randomized controlled trial; Safety;

    机译:临床结果;社区获得的肺炎;左氧氟沙星;Nemonoxacin;随机对照试验;安全;

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号